<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01244646</url>
  </required_header>
  <id_info>
    <org_study_id>NIS-CNL-DUM-2010/1</org_study_id>
    <nct_id>NCT01244646</nct_id>
  </id_info>
  <brief_title>Hypoglycemia- and Weight-related Quality of Life in Patients With Diabetes Mellitus Type 2 on Sulfonylurea Derivatives.</brief_title>
  <official_title>Perceived Hypoglycemia- and Weight-related Quality of Life of Patients With Sulfonylurea Derivate-treated Diabetes Mellitus Type 2, a Non-interventional Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. A prospective, non-interventional study, 125 patients with Diabetes Mellitus Type2 will
           be enrolled, who, while on metformin, have a sub-optimal glycemic control and who thus
           will receive additional treatment with a sulfonylurea (SU) derivative. At the start and
           at 3 and 6 months, during regular visits to the patient's General Practitioner, the
           patients will complete a series of questionnaires (Patient Reported Outcomes, PROs)
           directed at diabetes in general, at fear for hypoglycemia, at body weight, at treatment
           compliance and at general wellbeing. These PROs are the worry subscale of the
           Hypoglycaemic Fear Survey, Impact of Weight on Quality of Life, revised Diabetes Symptom
           Checklist, Problem Areas In Diabetes, EuroQol EQ-5D and Medication Adherence Report
           Scale. In total 75 questions. The frequency of hypoglycemic symptoms, incidence of
           hypoglycemic events and body weight changes will be assessed and the level of adherence
           to treatment will be investigated.

        2. Diabetic patients, M/F, aged &gt;35, metformin treated, serum HbA1c â‰¥7.0% (within last
           month), informed consent provided, in whom a SU therapy is added. Patients with Type 1
           diabetes and with secondary diabetes will be excluded, and patients unable to understand
           and complete the questionnaires.

        3. Primary outcome variables are outcomes from HFS-w and IWQOL in relation to the frequency
           of hypoglycemic symptoms and body weight at 6 months and to weight change from 0 to 6
           months. Secondary outcome variables are the other PROs. The frequency of hypoglycemic
           symptoms, incidence of hypoglycemic events, changes in body weight and level of
           compliance will be addressed.

        4. The Intention To Treat analysis will be used, with Last Value Extended Forward from 3 to
           6 months in case of withdrawal after 3 months. Changes in outcome variables will be
           analysed by modelling time and potential dummy variables in a Generalized Estimating
           Equations analysis.

        5. Secondary, outcomes in HFS-w and IWQOL are compared with self-reported hypoglycemic
           symptoms, incidence of hypoglycemic events, body weight and change in body weight from 0
           to 6 months. Changes in all PRO's from 0 to 3 and 6 months, potential relationships
           between (changes in) the different questionnaires, such as with hypoglycemia symptoms,
           weight (changes) and treatment compliance will be evaluated. A search is done for
           baseline characteristics which predict outcomes and changes in PRO's, hypoglycemic
           symptoms, hypoglycemic events and weight changes.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Hypoglycemic Fear Survey (HFS) questionnaire</measure>
    <time_frame>0 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Hypoglycemic Fear Survey (HFS) questionnaire</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Hypoglycemic Fear Survey (HFS) questionnaire</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Impact of Weight on Quality of Life (IWQOL-Lite) questionnaire</measure>
    <time_frame>0 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Impact of Weight on Quality of Life (IWQOL-Lite) questionnaire</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Impact of Weight on Quality of Life (IWQOL-Lite) questionnaire</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diabetes Symptom Checklist (DSC-R) questionnaire,</measure>
    <time_frame>0 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetes Symptom Checklist (DSC-R) questionnaire,</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetes Symptom Checklist (DSC-R) questionnaire,</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication Adherence Report Scale (MARS-5) questionnaire</measure>
    <time_frame>0 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication Adherence Report Scale (MARS-5) questionnaire</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication Adherence Report Scale (MARS-5) questionnaire</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator-asked Symptoms of Hypoglycemia, hypoglycemic events, weight, compliance</measure>
    <time_frame>0 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator-asked Symptoms of Hypoglycemia, hypoglycemic events, weight, compliance</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator-asked Symptoms of Hypoglycemia, hypoglycemic events, weight, compliance</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">48</enrollment>
  <condition>Diabetes Mellitus Type 2</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Patients with Diabetes Mellitus Type 2</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        General practitioners, group practices in primary care, pharmacists
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetes Mellitus Type 2 for &gt; 6 months on treatment with only metformin for &gt;4 weeks

          -  HbA1c value &gt;7.0 and therefore a sulfonylurea derivative is added

          -  Able to complete a series of questionnaires

        Exclusion Criteria:

          -  Concomitant treatment with an other antidiabetic than metformin and SU derivative

          -  Contraindications for the use of metformin or SU derivative

          -  Concomitant diseases which may affect the patient's ability to complete study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. F.J. Snoek, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>VU University of Amsterdam</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Alkmaar</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gorinchem</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heerhugowaard</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heiloo</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hoogvliet</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lichtenvoorde</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Limmen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Maasbracht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Noord-Scharwoude</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poortvliet</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Spijkenisse</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tuitjenhorn</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vaassen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valkenswaard</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Voerendaal</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Volendam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wamel</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zuid-Scharwoude</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zutphen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2010</study_first_submitted>
  <study_first_submitted_qc>November 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2010</study_first_posted>
  <last_update_submitted>December 5, 2012</last_update_submitted>
  <last_update_submitted_qc>December 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Type 2</keyword>
  <keyword>DMT2</keyword>
  <keyword>T2DM</keyword>
  <keyword>metformin</keyword>
  <keyword>sulfonylurea</keyword>
  <keyword>hypoglycemia</keyword>
  <keyword>weight</keyword>
  <keyword>quality of life</keyword>
  <keyword>compliance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

